Sunesis Pharmaceuticals
Biotechnology, 395 Oyster Point Blvd., South San Francisco, California, 94080, United States, 11-50 Employees
Phone Number: 65********
Who is SUNESIS PHARMACEUTICALS
Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunes...
Read More
-
Headquarters: 395 Oyster Point Blvd., South San Francisco, California, 94080, United States
-
Date Founded: 1987
-
Employees: 11-50
-
Revenue: $50 Million to $100 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from SUNESIS PHARMACEUTICALS
Sunesis Pharmaceuticals Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Sunesis Pharmaceuticals
Answer: Sunesis Pharmaceuticals's headquarters are located at 395 Oyster Point Blvd., South San Francisco, California, 94080, United States
Answer: Sunesis Pharmaceuticals's phone number is 65********
Answer: Sunesis Pharmaceuticals's official website is https://sunesis.com
Answer: Sunesis Pharmaceuticals's revenue is $50 Million to $100 Million
Answer: Sunesis Pharmaceuticals's SIC: 2834
Answer: Sunesis Pharmaceuticals's NAICS: 325412
Answer: Sunesis Pharmaceuticals has 11-50 employees
Answer: Sunesis Pharmaceuticals is in Biotechnology
Answer: Sunesis Pharmaceuticals contact info: Phone number: 65******** Website: https://sunesis.com
Answer: Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. Our workpursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients Our workplacecreating a stimulating, teamwork-oriented environment for our people involved in this important work Our worldsupporting the larger oncology community and the philanthropic organizations that help patients and caregivers
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month